Therapeutic Asset Ratings

8,400 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Vinorelbine Leukemia	Memorial Sloan Kettering Cancer Center	P1/2	CCC (55)
Vorinostat Extranodal Nasal NK/T Cell Lymphoma	City of Hope Medical Center	P1/2	CCC (55)
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)- NHL	National Cancer Institute (NCI)	P1/2	CCC (54)
3hp-2827 Solid Tumors With FGFR2 Alterations, Adult	3H (Suzhou) Pharmaceuticals Co., Ltd.	P1/2	CCC (54)
ABATACEPT RECOMBINANT Amyotrophic Lateral Sclerosis	Massachusetts General Hospital	P1/2	CCC (54)
Abemaciclib Colorectal Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (54)
ag-120 Hematopoietic And Lymphoid System Neoplasm	M.D. Anderson Cancer Center	P1/2	CCC (54)
Allogeneic Cd8+ Leukemia-Associated Antigens Specific T Cells Nexi-001 Myelodysplastic Syndrome	City of Hope Medical Center	P1/2	CCC (54)
Anti-Bcma Car-Nk Cells Plasma Cell Myeloma	Shahid Beheshti University of Medical Sciences	P1/2	CCC (54)
Anti-Bcma Car T Cells Plasma Cell Myeloma	Hebei Senlang Biotechnology Inc., Ltd.	P1/2	CCC (54)
Anti-Bcma Car T Cells Multiple Myeloma Refractory	Hebei Senlang Biotechnology Inc., Ltd.	P1/2	CCC (54)
Atezolizumab Exocrine Pancreatic Carcinoma	OHSU Knight Cancer Institute	P1/2	CCC (54)
Atezolizumab Malignant Glioma	Mustafa Khasraw, MBChB, MD, FRCP, FRACP	P1/2	CCC (54)
Atezolizumab Soft Tissue Sarcoma	OHSU Knight Cancer Institute	P1/2	CCC (54)
Autologous Cd34+ Cells Transduced With Tns9.3.55 Beta-Thalassemia Major	Daniel Bauer	P1/2	CCC (54)
AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) OBTAINED BY APHERESIS TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING A CHIMERIC ANTIGEN RECEPTOR (CAR) CONSISTING OF AN ANTI-CD19 SPECIFIC SCFV, A CD8.ALPHA. STALK, TRANSMEMBRANE DOMAIN AND ANCHOR, A 41BB ENDODOMAIN AND A CD3 ZETA ENDODOMAIN, UNDER THE CONTROL OF A HUMAN PGK1 PROMOTER AND A MODIFIED WOODCHUCK POST TRANSCRIPTIONAL RESPONSE ELEMENT. THE VECTOR GENOME ALSO CONTAINS A 5' TERMINAL CMV ENHANCER/PROMOTER, A .PSI. PACKAGING SIGNAL, A REV RESPONSE ELEMENT (RRE) AND A CENTRAL POLYPURINE TRACT (CPPT) B-Cell Acute Lymphoblastic Leukemia	Autolus Limited	P1/2	CCC (54)
azd7789 Non-Small Cell Lung Carcinoma	AstraZeneca	P1/2	CCC (54)
Bbm-D101 DMD	Belief BioMed (Beijing) Co., Ltd	P1/2	CCC (54)
Benadryl Advanced Biliary Cancer	Merck Sharp & Dohme LLC	P1/2	CCC (54)
bl0020 Small Cell Lung Carcinoma	Shanghai Best-Link Bioscience, LLC	P1/2	CCC (54)
carbidopa Autonomic Nervous System Disorder	Daniel Claassen	P1/2	CCC (54)
Carboplatin Skin Squamous Cell Carcinoma	Rapa Therapeutics LLC	P1/2	CCC (54)
cc-5013 Folliculotropic Mycosis Fungoides	City of Hope Medical Center	P1/2	CCC (54)
cd5-targeted car-t cells T-Cell Non-Hodgkin Lymphoma	Beijing GoBroad Hospital	P1/2	CCC (54)
cd7.car/28zeta car t cells T-Lymphoblastic Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CCC (54)

Showing 276 to 300 of 8,400 assets

PreviousPage 12 of 336Next